247 related articles for article (PubMed ID: 28974549)
61. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
[TBL] [Abstract][Full Text] [Related]
62. Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo.
Gao N; Budhraja A; Cheng S; Liu EH; Huang C; Chen J; Yang Z; Chen D; Zhang Z; Shi X
Apoptosis; 2011 May; 16(5):511-23. PubMed ID: 21336837
[TBL] [Abstract][Full Text] [Related]
63. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263.
Polier G; Giaisi M; Köhler R; Müller WW; Lutz C; Buss EC; Krammer PH; Li-Weber M
Int J Cancer; 2015 Feb; 136(3):688-98. PubMed ID: 24895203
[TBL] [Abstract][Full Text] [Related]
64. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
65. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
66. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).
Lam LT; Lu X; Zhang H; Lesniewski R; Rosenberg S; Semizarov D
Mol Cancer Ther; 2010 Nov; 9(11):2943-50. PubMed ID: 20829195
[TBL] [Abstract][Full Text] [Related]
67. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
Scherr M; Kirchhoff H; Battmer K; Wohlan K; Lee CW; Ricke-Hoch M; Erschow S; Law E; Kloos A; Heuser M; Ganser A; Hilfiker-Kleiner D; Heidenreich O; Eder M
Leukemia; 2019 Jun; 33(6):1313-1323. PubMed ID: 30546081
[TBL] [Abstract][Full Text] [Related]
68. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
[TBL] [Abstract][Full Text] [Related]
69. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
70. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.
Tahir SK; Wass J; Joseph MK; Devanarayan V; Hessler P; Zhang H; Elmore SW; Kroeger PE; Tse C; Rosenberg SH; Anderson MG
Mol Cancer Ther; 2010 Mar; 9(3):545-57. PubMed ID: 20179162
[TBL] [Abstract][Full Text] [Related]
71. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
72. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
[TBL] [Abstract][Full Text] [Related]
73. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
74. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
75. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
76. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
77. Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.
Lin KH; Winter PS; Xie A; Roth C; Martz CA; Stein EM; Anderson GR; Tingley JP; Wood KC
Sci Rep; 2016 Jun; 6():27696. PubMed ID: 27283158
[TBL] [Abstract][Full Text] [Related]
78. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
79. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.
Scherr M; Elder A; Battmer K; Barzan D; Bomken S; Ricke-Hoch M; Schröder A; Venturini L; Blair HJ; Vormoor J; Ottmann O; Ganser A; Pich A; Hilfiker-Kleiner D; Heidenreich O; Eder M
Leukemia; 2014 Mar; 28(3):554-65. PubMed ID: 24280866
[TBL] [Abstract][Full Text] [Related]
80. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts.
Nocquet L; Roul J; Lefebvre CC; Duarte L; Campone M; Juin PP; Souazé F
Sci Rep; 2024 Jun; 14(1):14177. PubMed ID: 38898061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]